10-Q: Humana Inc. Reports Second Quarter 2024 Results, Impacted by Medicare Cost Trends

Humana Inc.'s second quarter 2024 results show a decrease in net income compared to the same period last year, primarily due to elevated Medicare Advantage medical costs and adjustments related to minority interest investments.

Summary

• Humana Inc. reported a net income of $679 million for the second quarter of 2024, a decrease from $959 million in the same quarter of 2023.
• Diluted earnings per common share were $5.62 for Q2 2024, down from $7.66 in Q2 2023.
• For the first six months of 2024, net income was $1.42 billion, compared to $2.2 billion for the same period in 2023.
• The company's revenue increased to $29.54 billion in Q2 2024 from $26.75 billion in Q2 2023, driven by higher premiums and services revenue.
• The benefit ratio increased to 89.0% in Q2 2024 from 86.3% in Q2 2023, primarily due to higher Medicare Advantage medical costs.
• Humana's operating cost ratio decreased to 10.8% in Q2 2024 from 11.8% in Q2 2023, due to administrative efficiencies and lower commission expenses.
• The company recorded charges of $68 million and $97 million for the three and six months ended June 30, 2024, respectively, related to value creation initiatives, primarily in asset impairments.
• Humana's Medicare Advantage membership grew to 5.6 million individual members and 544,900 group members, while Medicare stand-alone PDP membership decreased to 2.3 million.
• The company repurchased 1.9 million shares for $750 million during the first six months of 2024.

Sentiment

Score: 4

Explanation: The document presents mixed results with a significant decrease in net income and an increase in the benefit ratio, offset by improvements in operating costs and membership growth in key areas. The overall tone is cautious due to the challenges in managing medical costs and the competitive landscape.

Positives

• Humana's total revenue increased by 10.4% in Q2 2024 compared to Q2 2023.
• The operating cost ratio improved by 100 basis points in Q2 2024 compared to Q2 2023.
• Individual Medicare Advantage membership grew by 6.6% year-over-year.
• The company is actively pursuing value creation initiatives to improve efficiency and fund growth.

Negatives

• Net income decreased by 29.1% in Q2 2024 compared to Q2 2023.
• The benefit ratio increased by 270 basis points in Q2 2024 compared to Q2 2023.
• Medicare stand-alone PDP membership decreased by 19.7% year-over-year.
• The company incurred $68 million in charges related to value creation initiatives in Q2 2024.

Risks

• Elevated Medicare Advantage medical cost trends are negatively impacting the benefit ratio.
• The company is facing increased competition in the Medicare stand-alone PDP market.
• The exit from the Employer Group Commercial Medical Products business is impacting membership and revenue.
• The Final RADV Rule could have a material adverse effect on the company's financial results.
• The company is subject to various legal proceedings and regulatory matters that could have a material adverse effect on its financial position.

Future Outlook

The company expects to incur additional charges related to value creation initiatives through the end of 2024. Humana believes its integrated care delivery model positions it for long-term growth in both membership and earnings.

Management Comments

• Humana is committed to putting health first for its teammates, customers, and company.
• The company's strategy offers members affordable healthcare combined with a positive consumer experience in growing markets.
• Humana's approach to primary, physician-directed care aims to provide quality care that is consistent, integrated, cost-effective, and member-focused.

Industry Context

The results reflect the ongoing challenges in the healthcare industry, particularly with rising medical costs and the competitive landscape of Medicare Advantage and Part D plans. The company's strategic shift towards integrated care delivery and value-based arrangements aligns with broader industry trends focused on improving health outcomes and affordability.

Comparison to Industry Standards

• Humana's benefit ratio increase reflects a broader trend of rising medical costs impacting health insurers, similar to what has been reported by UnitedHealth Group and CVS Health.
• The company's operating cost ratio improvement is a positive sign, indicating efficiency gains, which is a key focus for many large healthcare companies like Anthem and Cigna.
• The decline in Medicare stand-alone PDP membership is consistent with the industry-wide trend of increased competition and consolidation in this market, impacting companies like Centene and Wellcare.
• Humana's focus on value-based care is in line with the industry's move away from fee-for-service models, similar to initiatives by companies like Oak Street Health and ChenMed.

Legal Proceedings

• Humana is involved in a lawsuit regarding the Final RADV Rule.
• A putative stockholder class action was filed against Humana and certain of its current and former executive officers.
• A parallel stockholder derivative action was filed against certain of Humana's current and former directors and executive officers.
• The company is subject to various other lawsuits and regulatory matters.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and earnings per share.
• Members may experience changes in benefits and premiums due to the company's strategic adjustments.
• Employees may be affected by the company's value creation initiatives and restructuring efforts.
• Providers may be impacted by the company's shift towards value-based care arrangements.

Next Steps

• The company will continue to implement its value creation initiatives.
• Humana will monitor and manage medical cost trends.
• The company will continue to focus on growing its Medicare Advantage business.
• Humana will continue to work with CMS to promote the integrity of the MA program.

Key Dates

Keywords

Medicare Advantage, Healthcare, Insurance, Financial Results, Medical Costs, Membership, Earnings, Benefit Ratio, Operating Costs, Humana